Genome Biologics
Genome Biologics is a pioneering biotech company focused on developing therapies for cardiovascular and cardiometabolic diseases. They leverage AI-driven big data analysis and advanced disease modeling technologies to accelerate drug discovery and preclinical validation. Their mission is inspired by patients and driven by data, aiming to address unmet medical needs in heart health.
Industries
Nr. of Employees
small (1-50)
Genome Biologics
Centre for Molecular Medicine, Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Patents
Products
Cardiotoxicity cardioprotective candidate (metabolic modulation)
Therapeutic program aimed at metabolic modulation to protect against cancer treatment–induced cardiotoxicity; program reported at IND/CTA filing stage.
Heart failure mitochondrial modulator (HF-rEF)
Program targeting mitochondrial modulation to treat heart failure with reduced ejection fraction; program reported at IND/CTA filing stage.
Cardiac regeneration RNAi candidate
RNAi-based therapeutic program aimed at inducing cardiomyocyte proliferation and cardiac regeneration; compounds validated in preclinical models and reported at IND/CTA filing stage.
Kearns–Sayre Syndrome metabolic modulation program
Preclinical discovery program targeting metabolic modulation for Kearns–Sayre Syndrome (mitochondrial disorder); program in preclinical discovery stage.
Cardiotoxicity cardioprotective candidate (metabolic modulation)
Therapeutic program aimed at metabolic modulation to protect against cancer treatment–induced cardiotoxicity; program reported at IND/CTA filing stage.
Heart failure mitochondrial modulator (HF-rEF)
Program targeting mitochondrial modulation to treat heart failure with reduced ejection fraction; program reported at IND/CTA filing stage.
Cardiac regeneration RNAi candidate
RNAi-based therapeutic program aimed at inducing cardiomyocyte proliferation and cardiac regeneration; compounds validated in preclinical models and reported at IND/CTA filing stage.
Kearns–Sayre Syndrome metabolic modulation program
Preclinical discovery program targeting metabolic modulation for Kearns–Sayre Syndrome (mitochondrial disorder); program in preclinical discovery stage.
Services
Computational analysis of multiomics and transcriptomic datasets to identify disease drivers and match existing compounds or novel targets for repositioning or precision indication development.
Design and execution of multiplexed gain-of-function transgenic studies and simultaneous gene-family validation in cell-based systems and small/large animal models for therapeutic assessment.
Computational analysis of multiomics and transcriptomic datasets to identify disease drivers and match existing compounds or novel targets for repositioning or precision indication development.
Design and execution of multiplexed gain-of-function transgenic studies and simultaneous gene-family validation in cell-based systems and small/large animal models for therapeutic assessment.
Expertise Areas
- Cardiovascular and cardiometabolic drug discovery
- Preclinical disease modelling and translational validation
- AI-driven target identification and multiomics integration
- Multiplexed transgenesis and large-animal modeling
Key Technologies
- AI-driven big data analytics
- Multiomics integration
- Transcriptomics
- Genomics
News & Updates
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programmes for the prevention of cardiotoxicity and heart damage.
Genome Biologics enters into a research collaboration and exclusive license option agreement with AstraZeneca to identify drivers of cardiac regeneration and recovery in Myocardial Infarction, Heart Failure and Cardiotoxicity.
Research by Genome Biologics was highlighted in Nature Reviews Cardiology.
Genome Biologics was recognized as one of the top 100 fastest growing startups in Germany.
Genome Biologics was listed among the top 5 AI-driven drug discovery startups impacting the industry.
Recognized as one of the top 10 AI and drug discovery companies in Europe.
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programmes for the prevention of cardiotoxicity and heart damage.
Genome Biologics enters into a research collaboration and exclusive license option agreement with AstraZeneca to identify drivers of cardiac regeneration and recovery in Myocardial Infarction, Heart Failure and Cardiotoxicity.
Research by Genome Biologics was highlighted in Nature Reviews Cardiology.
Genome Biologics was recognized as one of the top 100 fastest growing startups in Germany.
Genome Biologics was listed among the top 5 AI-driven drug discovery startups impacting the industry.
Recognized as one of the top 10 AI and drug discovery companies in Europe.